Clinical characteristics and outcomes with specific <i>BRAF</i> and <i>NRAS</i> mutations in patients with metastatic melanoma

Abstract

The presence of different substitutions at BRAF V600 correlates with patient demographics, tumor characteristics, and prognosis. These findings demonstrate the presence of mutation-specific clinical differences between different BRAF genotypes in patients with melanoma, and support the incorporation of this information in patient evaluation and clinical trial design.